输注体外活化的自身淋巴细胞治疗晚期恶性肿瘤  

BIOTHERAPY OF ADVANCED CANCER BY INFUSION OF IN VITRO ACTIVATED AUTOLYMPHOCYTES

作　　者：杜献堂[1] 张明智[1] 赵曼瑞[1] 王瑞林[1] 吕先萍[1] 张克勤[1] 

机构地区：[1]河南医科大学微生物学教研室,河南医科大学肿瘤研究所,河南医科大学第一附属医院血库

出　　处：《中华肿瘤杂志》1995年第6期464-466,共3页Chinese Journal of Oncology

基　　金：河南省科委科技攻关

摘　　要：自身淋巴细胞生物学疗法是一种可以门诊施行的治疗晚期恶性肿瘤的过继免疫疗法。其主要程序是输注体外用抗ＣＤ３单克隆抗体等活化的，用甲氰咪胍和低剂量γ射线等去除或抑制Ｔ抑制细胞活性的自身淋巴细胞。病人同时服用甲氰咪胍以去除或抑制体内Ｔ抑制细胞的活性。作者共治疗患者６５例，２１７人次，除１０例１８人次在回输时有轻微类似输液反应的寒颤伴暂时的轻度体温升高外，未见其它毒性反应。对其中３７例输注治疗３次以上的病人，进行临床疗效分析，缓解率（ＣＲ＋ＰＲ）为２４％，有效率（ＣＲ＋ＰＲ＋ＭＲ）为５１％。自身淋巴细胞生物学疗法疗效与文献报道的ＬＡＫ疗法相似，但费用低廉，副作用和毒性较低。AbstractAutolymphocyte biotherapy is an adoptive cellular therapy based upon the infusion of autolo-gous lymphocytes that have been activated in vitro by anti-CD3 monoclonal antibody and depletedof suppressor T cells by cimetidine,indomethacin and low dose of γ irradiation. The patients alsoreceive oral cimetidine to block suppressor T cell activity in vivo. Sixty five patients received 217autolymphocyte infusions and toxicity was minimal with transient fever and chill accompanying 18ifusions.The efficacy of treatment in patients received more than 3 infusions were evaluated.In37 evaluable patients,the response rate(CR +PR)was 24%(9/37 ).As the side reactions aremild,the treatment can be done on an outpatient basis.

关 键 词：肿瘤 免疫疗法 淋巴细胞 体外活化 

分 类 号：R730.51[医药卫生—肿瘤]